Psilocybin

Psilocybin is a prodrugan inactive compound your body converts into the active drug with little intrinsic activity at serotonina mood, calm, and well-being neurotransmitter receptors; its effects depend on rapid conversion to psilocin. Following oral ingestion, alkaline phosphatase (and to a lesser degree other enzymes) removes the 4-phosphoryloxy group to yield psilocin (4-hydroxy-N,N-dimethyltryptamine), which is lipophilicfat-loving; crosses cell membranes and the brain easily enough to cross the blood-brain barrierthe filter that decides what gets from your blood into your brain and reach dose-dependent plasma and brain concentrations. Psilocin then acts as an agonistsomething that switches a receptor on or partial agonist at serotonin 5-HT2Aa serotonin receptor tied to mood, perception, and plasticity receptors, the shared molecular target of the classic psychedelics, with additional activity at 5-HT2C and 5-HT1Aa serotonin receptor tied to calm and anxiety relief receptors. Agonism at 5-HT2A receptors on cortical pyramidal neurons alters cortical excitability and large-scale network dynamics, and human arterial spin labeling studies show that psilocin reduces cerebral blood flow and constricts the internal carotid artery, effects blocked by the 5-HT2A antagonistsomething that blocks a receptor ketanserin, confirming the receptor as central to its physiology.

Beyond the acute experience, psilocybin's therapeutic potential is linked to neuroplastic changes. Its active metabolitea breakdown product your body makes from a compound promotes markers of neuronal plasticity, and emerging work implicates additional targets beyond canonical cell-surface 5-HT2Aa serotonin receptor tied to mood, perception, and plasticity signaling, including biased agonism, intracellular 5-HT2A receptor pools accessible to lipophilicfat-loving; crosses cell membranes and the brain easily psychedelics, and downstream engagement of neurotrophic pathways. Functional MRI in patients with depression has shown that antidepressant response to psilocybin correlates with decreased brain network modularity, that is, a global increase in network integration and flexibility among 5-HT2A-rich higher-order networks, a change not seen with escitalopram. Psilocin is metabolized through Phase I and Phase II routes, notably glucuronidation to psilocin-O-glucuronide, with an elimination half-lifehow long it takes for half a dose to clear your system of roughly two to three hours, which accounts for the four-to-six-hour duration of the psilocybin experience.